What Is the Downside of the HoLEP Procedure?

HoLEP is widely regarded as one of the most durable surgeries for enlarged prostates, but it comes with a recovery that catches many men off guard. The procedure’s biggest downsides include near-universal retrograde ejaculation, weeks of painful urination, temporary urinary leakage in a meaningful fraction of patients, and a steep surgical learning curve that means outcomes depend heavily on your surgeon’s experience. None of these are reasons to avoid HoLEP if you genuinely need it, but understanding each one helps set realistic expectations for what the first few months look like.

Dysuria Is Intense and Lasts Longer Than Most Men Expect

The most common complaint after HoLEP is painful or burning urination, known as dysuria. A prospective study tracking patients week by week found that about three-quarters reported moderate-to-severe dysuria during the first postoperative week. That dropped to roughly 40% by week three and about 18% by week eight. From week twelve onward it became uncommon, and by six months only about 1% of patients still had significant burning.

That timeline matters because many men hear “minimally invasive laser surgery” and assume they will feel normal within days. The reality is more like two to three months of gradually improving discomfort, with the worst concentrated in the first few weeks. A randomized controlled study found that using a catheter coated with local anesthetic reduced pain scores on the day of surgery, but the effect was modest and did not eliminate the issue.

Urgency often accompanies the burning, with sudden strong urges to urinate that can feel worse than the symptoms that prompted surgery in the first place. This is temporary, but it can be demoralizing if you are not prepared for it. A prospective satisfaction study confirmed that urgency-related incontinence was the most common reason patients expressed dissatisfaction after the procedure.

Retrograde Ejaculation Happens to Nearly Everyone

If preserving normal ejaculation matters to you, this is the single biggest downside. HoLEP removes the inner tissue of the prostate so thoroughly that the mechanism directing semen forward through the urethra is almost always disrupted. A large retrospective study of 535 patients found that roughly 93% reported retrograde ejaculation afterward, meaning semen travels backward into the bladder instead of exiting normally.

⁴

Despite how common it is, retrograde ejaculation is physically harmless. The semen is simply flushed out the next time you urinate. What varies is how much it bothers men psychologically and in their relationships. The same study found that the mere presence of retrograde ejaculation was not independently linked to lower satisfaction with sex life overall. However, among the men who said they felt bothered by it, sexual satisfaction dropped significantly. Men with stronger erectile function tended to be less bothered, suggesting that when the rest of sexual function is intact, the absence of visible ejaculate is easier to live with.

⁴

A separate study using validated questionnaires found that ejaculatory function scores declined significantly after HoLEP, with reductions in ejaculatory ability, strength, and volume. Erectile function scores, however, did not decline significantly.

⁵

The practical implication: if you are still hoping to father children naturally, HoLEP will almost certainly make that impossible without assisted reproductive techniques. If fertility is not a concern and your erectile function is reasonable, most men adjust to the change, but it is worth an honest conversation with yourself and your partner before surgery.

Temporary Urinary Incontinence

Leaking urine after HoLEP is common in the short term, less so in the long run. A meta-analysis pooling data from nearly 8,000 patients found that incontinence rates dropped substantially over time, with the incidence of permanent urinary incontinence settling at around 1%.

⁶

What does the early period actually look like? A single-surgeon series of 589 patients found that about 9% developed stress urinary incontinence (leaking with coughing, sneezing, or straining). The encouraging part: in nearly 90% of those men, it resolved within six weeks. Only about 1.5% developed long-term incontinence requiring intervention, and even those men eventually achieved continence, though it took an average of roughly 16 months.

⁷

Prostate size matters here. A registry-based study of over 1,600 patients found that larger prostates were associated with higher incontinence rates at two weeks. By six months, about 1.2% still had stress incontinence, and no patients in that cohort needed secondary surgery such as a sling or artificial sphincter.

⁸

Pelvic floor exercises can help speed recovery. A randomized study found that starting pelvic floor muscle exercises four weeks before surgery, then continuing afterward, improved early continence compared to starting exercises only after the procedure.

⁹

Bleeding Risks, Especially on Blood Thinners

HoLEP generally causes less blood loss than the older standard procedure, TURP, because the laser seals blood vessels as it cuts.

¹⁰

That said, bleeding is not negligible. A large multicenter analysis of roughly 1,000 HoLEP patients found that about 5% required a blood transfusion during or shortly after the procedure, with a measurable drop in hemoglobin levels across the board.

¹¹

Blood thinners complicate the picture. A retrospective analysis from a high-volume center found that within 30 days of surgery, about 3.5% of all patients were readmitted for persistent blood in the urine, and about 2.4% needed a transfusion. Patients on anticoagulants had significantly higher readmission and transfusion rates compared to those not on blood thinners, with readmission rates reaching 16% for men on anticoagulants versus 2% for those on antiplatelet therapy alone.

¹²

The question of whether to stop or continue blood thinners around HoLEP does not have a clean answer. One retrospective study found no significant difference in outcomes between patients who held their blood thinners and those who continued them.

¹³

A prospective cohort study similarly found no significant increase in transfusion rates, cardiovascular events, or cerebrovascular events in patients receiving antithrombotic therapy.

¹⁴

However, the higher complication rates seen in other analyses suggest that patients on anticoagulants do face elevated bleeding risk overall. Another study confirmed a higher 90-day complication rate in antiplatelet and anticoagulant groups, even though emergency department visits and severe complications were not significantly different.

¹⁵

Men with prostate cancer may also face elevated bleeding risk. A multicenter cohort study found that postoperative transfusion was more frequent in men with prostate cancer compared to those without, with rates of about 6% versus 2%.

¹⁶

The Steep Learning Curve for Surgeons

HoLEP is technically demanding in a way that directly affects patient outcomes. A multicenter prospective study evaluating surgeons who were learning the technique found that the learning curve exceeded 20 cases, and nearly half the participating centers chose to abandon the technique entirely. Operating time and difficulty of the enucleation step were the primary problems for beginners.

¹⁷

This has a practical consequence for patients: not all hospitals or urologists offer HoLEP, and among those who do, experience levels vary widely. A surgeon who has done 30 cases is in a different position than one who has done 300. If you are considering HoLEP, asking about your surgeon’s case volume and complication rates is entirely reasonable and arguably necessary. Complications like bladder injury, prolonged operating time, and incomplete enucleation are all more likely early in a surgeon’s learning curve.

Longer Operating Time and Hospital Stay Versus Alternatives

Compared to TURP, HoLEP takes longer in the operating room. A prospective randomized study directly comparing the two for larger prostates confirmed that HoLEP is associated with longer operative time but also less blood loss, lower transfusion rates, and shorter hospital stays.

¹⁰

The difference is more dramatic when comparing HoLEP to newer minimally invasive options like the Rezūm water vapor therapy. A matched-pair analysis found that Rezūm averaged about 8 minutes of procedure time compared to roughly 68 minutes for HoLEP. Hospital stay was also shorter with Rezūm. However, HoLEP significantly outperformed Rezūm in urinary flow rates and symptom improvement at 12 months.

¹⁸

So the tradeoff is real: HoLEP means more time under anesthesia and a longer in-hospital stay, but the functional results tend to be superior and more durable. Whether that tradeoff is worth it depends on your prostate size, your symptoms, and how much the sexual side effects matter to you.

Urethral Stricture and Bladder Neck Contracture

These are late complications that can develop months after surgery. A urethral stricture is a narrowing of the urethra caused by scar tissue, while a bladder neck contracture is scarring where the bladder meets the prostate cavity. Both can cause difficulty urinating and may require additional procedures to fix.

An eight-year single-center analysis found that about 2% of HoLEP patients developed a urethral stricture, appearing on average around six months after surgery. Most of these strictures were short (under 1 cm) and initially treated with dilation or laser incision. However, about a quarter recurred and needed further treatment.

¹⁹

How does this compare to TURP? A matched dual-center study found stricture rates of about 5% for HoLEP and 8% for TURP, with bladder neck contracture occurring in about 2% of the HoLEP group. The differences were not statistically significant, but the trend slightly favored HoLEP.

²⁰

Over longer follow-up, a study with a median of 7.6 years found that about 4.3% of patients eventually needed reoperation for any reason, including roughly 2% for urethral stricture and 1% for bladder neck contracture. Freedom from any reoperation was about 97% at five years and 95% at ten years.

²¹

Morcellation and Bladder Injury

After the laser enucleates the prostate tissue, the loosened pieces need to be broken up and suctioned out of the bladder. This step, called morcellation, involves a spinning blade inside the bladder, and it carries a small risk of injuring the bladder wall. Reported bladder injury rates during morcellation range from about 0.5% to as high as 18% depending on how injury is defined and detected.

²²

Most morcellation injuries are superficial nicks that heal without intervention. Full-thickness injuries are rare but more serious because irrigation fluid can leak into the surrounding tissue or abdominal cavity. A prospective European study found that neither the type of enucleation technique nor the specific morcellator used independently predicted more severe injuries, which suggests that surgical experience is the bigger factor.

²³

Acute Urinary Retention After Catheter Removal

After HoLEP, a catheter typically stays in overnight and is removed the next day. Some men cannot urinate once it comes out. A study of 337 patients found that about 11% experienced postoperative urinary retention. In most cases, the cause was blood clots blocking the urethra, and the issue resolved within a couple of days on average. The strongest predictors of retention were complications related to morcellation efficiency and bleeding, not prostate size or age.

²⁴

This is usually a short-lived problem, but it means an extra day or two in the hospital and the discomfort of having the catheter reinserted. For men traveling to a specialized center for their HoLEP, it is worth factoring in the possibility that you may not go home as quickly as planned.

How HoLEP Compares to Less Invasive Options

The downsides of HoLEP look different when stacked against specific alternatives. The matched comparison with Rezūm is illustrative. Rezūm preserved antegrade ejaculation in about 95% of patients, compared to roughly 5% for HoLEP. Transient incontinence rates were also much lower with Rezūm, at about 1.5% versus 28% for HoLEP.

¹⁸

But HoLEP produced significantly better urinary flow and symptom scores at one year, and patient satisfaction scores were similar between the two. A systematic review of longer-term data found that HoLEP demonstrated durable outcomes with a mean reoperation rate of about 4% over a mean follow-up of seven years.

²⁵

Less invasive procedures like Rezūm and UroLift tend to be better at preserving sexual function but may not last as long and may not be suitable for very large prostates. HoLEP can handle prostates of virtually any size, which is its biggest structural advantage. The “right” choice depends on where your priorities fall on the spectrum between preservation of ejaculation and maximum long-term symptom relief.

The Gap Between Expectations and Recovery

A recurring theme in the HoLEP literature is that patients are often surprised by how rough the recovery feels despite being told about it beforehand. One study specifically examining patient expectations noted that despite preoperative consultation, there is little evidence that physician-patient communication effectively prepares men for the variable recovery period involving hematuria, dysuria, and incontinence.

²⁶

The mismatch is understandable. HoLEP is marketed as a “gold standard” laser procedure, which can sound futuristic and gentle. In reality, it is an aggressive and thorough removal of tissue performed through the urethra. The word “laser” gives a false sense of minimalism. Knowing that three-quarters of men will have significant burning in week one, that leaking is common for weeks, and that your ejaculation will almost certainly change permanently is the kind of information that should shape your mental preparation just as much as your decision to proceed.

Incidental Prostate Cancer Detection

One unusual aspect of HoLEP is that because it removes large amounts of prostate tissue, the pathology report sometimes reveals cancer that no one knew was there. A single-center study found incidental prostate cancer in about 14% of HoLEP specimens. Most were low-grade, but roughly 11% were high-grade tumors that warranted further evaluation and possible treatment.

²⁷

This is arguably an upside, since catching cancer early is generally better than not catching it. But it can also be psychologically jarring. You go in for a benign prostate procedure and come out with a cancer diagnosis, even if the cancer turns out to be low-risk and manageable. The emotional whiplash is real, and it is worth being aware that pathology results after HoLEP sometimes deliver news you were not expecting.